CEFAZOLIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H14N8O4S3
Molecular Weight	454.507
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O

InChI

InChIKey=MLYYVTUWGNIJIB-BXKDBHETSA-N

InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=686cd696-0011-47b2-b342-142c20169ac6

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 232 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3266730	Inhibitor 8146

Conditions

Condition	Modality	Highest Phase	Product
Respiratory tract infections 85 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=686cd696-0011-47b2-b342-142c20169ac6	Curative	Approved 8307	ANCEF Approved Use Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1.18540796E11
Urinary tract infections 202 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=686cd696-0011-47b2-b342-142c20169ac6	Curative	Approved 8307	ANCEF Approved Use Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1.18540796E11
Sepsis 71 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=686cd696-0011-47b2-b342-142c20169ac6	Curative	Approved 8307	ANCEF Approved Use Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1.18540796E11
Genital Infections 4 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=686cd696-0011-47b2-b342-142c20169ac6	Curative	Approved 8307	ANCEF Approved Use Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1.18540796E11

C_max

Value	Dose	Co-administered	Analyte	Population
280.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050779s025lbl.pdf	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:		CEFAZOLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
509.9 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050779s025lbl.pdf	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:		CEFAZOLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.01 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050779s025lbl.pdf	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:		CEFAZOLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/526003/	healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/526003/	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/526003/
1.5 g 8 times / day multiple, intravenous Highest studied dose Dose: 1.5 g, 8 times / day Route: intravenous Route: multiple Dose: 1.5 g, 8 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4147580/	unhealthy, 21-34 years n = 4 Health Status: unhealthy Condition: endocarditis Age Group: 21-34 years Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/4147580/	Sources: https://pubmed.ncbi.nlm.nih.gov/4147580/
1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3510836/	healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3510836/	Other AEs: Pseudomembranous colitis... Other AEs: Pseudomembranous colitis Sources: https://pubmed.ncbi.nlm.nih.gov/3510836/
1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00610987	unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT00610987	Other AEs: Infection... Other AEs: Infection (serious, 15 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00610987

AEs

AE	Significance	Dose	Population
Rash	14.3% Disc. AE	4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/526003/	healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/526003/
Pseudomembranous colitis		1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3510836/	healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3510836/
Infection	serious, 15 patients	1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00610987	unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT00610987

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT4 145 OAT1 584 OAT3 625

Drug as perpetrator

Target	Modality	Activity
OAT4 145	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12650826/	yes [Ki 1740 uM]
OAT1 588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12650826/	yes [Ki 180 uM]
OAT3 627	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12650826/	yes [Ki 550 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:474053	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:474053
ChemicalBook	CB3396249	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3396249
MolPort	MolPort-002-507-461	https://www.molport.com/shop/molecule-link/MolPort-002-507-461
ZINC	ZINC000003830405	http://zinc15.docking.org/substances/ZINC000003830405

PubMed

Title	Date	PubMed
Double-blind comparison of phlebitis associated with cefazolin and cephalothin.	1976 Jul	789268
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera.	1981 Jan	6166604
Antigenicity of beta-lactam antibiotic preparations: production of IgE antibodies to beta-lactam antibiotic and their cross-reaction within the antibiotic group.	1982	6176550
Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins.	1990	2083978
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.	1999 Nov 5	10576583
Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.	2001	11706922
Use of charge-transfer complexation in the spectrophotometric analysis of certain cephalosporins.	2001 Jul 6	18968341
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution.	2002 Dec 1	12489379
Differences in neutrophil death among beta-lactam antibiotics after in vitro killing of bacteria.	2002 Jul	12095137
Effect of water content on the solid-state stability in two isomorphic clathrates of cephalosporin: cefazolin sodium pentahydrate (alpha form) and FK041 hydrate.	2002 Jun	12045330
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.	2002 Nov	12569987
The effect of additives on the crystallization of cefazolin sodium during freeze-drying.	2003 Feb	12636169
The effects of some antibiotics on sheep lens glucose 6-phosphate dehydrogenase in vitro.	2003 Mar	12696635
Antibiotic activity and synergistic effect of antimicrobial peptide against pathogens from a patient with gallstones.	2004 Aug 27	15358153
Efficacy of a non-vancomycin-based peritoneal dialysis peritonitis protocol.	2005 Apr	15877673
Effect of isoniazid on the pharmacodynamics of cefazolin-induced seizures in rats.	2005 Apr	15855723
[Sensitivity of nanoparticlized cefazolin sodium to the bacteria in vitro].	2005 Jun	16045023
Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1.	2005 Oct 1	16098483
Stability of cefazolin sodium in four heparinized and non-heparinized dialysate solutions at 38 degrees C.	2006 Sep-Oct	16973516
[Simultaneous spectrophotometric determination of certain beta-lactam antibiotics in rabbit serum using multivariate calibration methods].	2007 Feb	17514975
Conventional and dense gas techniques for the production of liposomes: a review.	2008	18597175
[Physical and chemical characteristics of a new cefazolin sodium hydrate crystal].	2008 Aug	18956782
Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter.	2008 Jun 17	18452908
Treatment of sinusitis with corticosteroids in combination with antibiotics in experimentally induced rhinosinusitis.	2008 May	18564537
Trends in antibacterial use in US academic health centers: 2002 to 2006.	2008 Nov 10	19001203
[Retropharyngeal abscesses: a retrospective analysis of 10 patients].	2008 Sep-Oct	19155676
[Antibiotic susceptibility of pathogenic bacteria isolated from 893 children with lower respiratory infection in Guiyang].	2009 Dec	20113598
Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat.	2009 Dec 3	19997621
Color selectivity of neurons in the posterior inferior temporal cortex of the macaque monkey.	2010 Jul	19880593
Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation.	2010 Nov	20694724
Sensitive chemiluminescence determination of thirteen cephalosporin antibiotics with luminol-copper(II) reaction.	2010 Oct	20925986
Piezoelectric immunosensors for the detection of individual antibiotics and the total content of penicillin antibiotics in foodstuffs.	2014 Mar	24468375
Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.	2015 Mar	25418905
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours

Route of Administration: Other

In Vitro Use Guide

Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.

Name

Type

Language

CEFAZOLIN

Official Name

English

CEFAZOLIN [MI]

Common Name

English

cefazolin [INN]

Common Name

English

CEFAZOLIN [USP MONOGRAPH]

Common Name

English

Cefazolin [WHO-DD]

Common Name

English

(6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Systematic Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-7-(((1H-TETRAZOL-1-YL)ACETYL)AMINO)-(6R-TRANS)

Common Name

English

J01DB04

Code

English

CEFAZOLIN [VANDF]

Common Name

English

CEFAZOLIN [HSDB]

Common Name

English

CEFAZOLIN [MART.]

Common Name

English

CEFAZOLIN [USP-RS]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000011161